Immune checkpoint inhibitors (ICIs) such as programmed cell death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) have altered the clinical treatment landscape for lung cancer due to unprecedented improved clinical outcome. This evidence concerns the gene PDCD1 and lung cancer.